文章摘要
王 容,周 焱,赵 川,李 毅,杨 凤.莫西沙星治疗耐药肺结核的临床疗效及机制研究[J].,2017,17(13):2524-2527
莫西沙星治疗耐药肺结核的临床疗效及机制研究
Curative Efficacy and Mechanisms of Moxifloxacin in the Treatment of Drug-resistant Tuberculosis
投稿时间:2016-11-14  修订日期:2016-11-29
DOI:10.13241/j.cnki.pmb.2017.13.032
中文关键词: 耐药肺结核  莫西沙星  白细胞介素-1  白细胞介素-6  肿瘤坏死因子-α  免疫功能
英文关键词: Drug-resistant tuberculosis  Moxifloxacin  Interleukin 1  Interleukin 6  Tumor necrosis factor alpha  Immune function
基金项目:四川省卫生厅基金项目(150244)
作者单位
王 容 遂宁市中心医院 感染科 四川 遂宁 629000 
周 焱 四川大学华西附属第一医院 老年医学中心/干部医疗科 四川 成都 610000 
赵 川 遂宁市中心医院 感染科 四川 遂宁 629000 
李 毅 遂宁市中心医院 感染科 四川 遂宁 629000 
杨 凤 遂宁市中心医院 感染科 四川 遂宁 629000 
摘要点击次数: 266
全文下载次数: 105
中文摘要:
      摘要 目的:探讨莫西沙星治疗耐药肺结核的临床疗效及可能机制。方法:选择2013年2月-2015年2月于我院门诊诊治的108例耐药肺结核,参照抽签法分为对照组和观察组,均54例,对照组采用左氧氟沙星治疗,观察组采用莫西沙星治疗,比较两组临床疗效、血清白细胞介素-1(IL-1)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)水平、CD3+、CD4+、CD8+、CD4+/CD8+、TOS、TAS、OSI和副反应的发生情况。结果:观察组治疗有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组血清IL-1,IL-6,TNF-α,TOS及OSI水平显著低于对照组,CD3+、CD4+、CD8+、TAS水平明显高于对照组,差异有统计学意义(P<0.05)。两组副反应发生情况比较差异无统计学意义(P>0.05)。结论:莫西沙星治疗耐药肺结核的临床疗效高,可能与减轻机体炎症反应和氧化应激水平及改善免疫功能有关。
英文摘要:
      ABSTRACT Objective: To study the efficacy and possible mechanism of moxifloxacin in the treatment of drug-resistant tuberculo- sis. Methods: 108 cases of patients with drug-resistant tuberculosis who were treated from February 2013 to February 2015 in our hospital were selected and divided into the control group and the observation group according to the drawing method with 54 cases in each group. The control group was treated by levofloxacin, while the observation group was treated with moxifloxacin. The clinical curative effect, serum interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-α(TNF-α) levels, CD3+, CD4+, CD8+, CD4+/ CD8+, TOS, TAS, OSI and the occurrence of adverse events of two groups were compared. Results: The effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the serum IL-1, IL-6, TNF-α, TOS, OSI of observation group were significantly lower than those of the control group, the CD3+, CD4+, CD8+, TAS levels of observation group obviously higher than those of control group(P<0.05). There was no significant difference in the incidence of side effects between two groups (P>0.05). Conclusion: Moxi- floxacin was effective in the treatment of drug-resistant tuberculosis, which could reduce the serum IL-1, IL-6, TNF-α levels and improve the immune function.
查看全文   查看/发表评论  下载PDF阅读器
关闭